324 related articles for article (PubMed ID: 7545416)
1. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
Levesque MA; Clark GM; Yu H; Diamandis EP
Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
[TBL] [Abstract][Full Text] [Related]
2. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer.
Yu H; Levesque MA; Khosravi MJ; Papanastasiou-Diamandi A; Clark GM; Diamandis EP
Br J Cancer; 1996 Oct; 74(8):1242-7. PubMed ID: 8883411
[TBL] [Abstract][Full Text] [Related]
3. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer.
Levesque MA; Diamandis EP; Yu H; Sutherland DJ
Breast Cancer Res Treat; 1994; 30(2):179-95. PubMed ID: 7524772
[TBL] [Abstract][Full Text] [Related]
7. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
8. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
10. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
11. DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers.
Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
Oncology; 2002; 63(1):48-55. PubMed ID: 12187071
[TBL] [Abstract][Full Text] [Related]
12. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
14. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
Elledge RM; Clark GM; Chamness GC; Osborne CK
J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
16. Relationship between low estrogen receptor values and other prognostic factors in primary breast tumors.
Gaffney EV; Halpin DP; Blakemore WS
Surgery; 1995 Mar; 117(3):241-6. PubMed ID: 7878527
[TBL] [Abstract][Full Text] [Related]
17. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
19. Detection of prostate-specific antigen immunoreactivity in breast tumors.
Diamandis EP; Yu H; Sutherland DJ
Breast Cancer Res Treat; 1994; 32(3):301-10. PubMed ID: 7532468
[TBL] [Abstract][Full Text] [Related]
20. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers.
Moe RE; Moe KS; Porter P; Gown AM; Ellis G; Tapper D
Am J Surg; 1991 May; 161(5):580-3. PubMed ID: 1674411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
